Role of darolutamide in intensification of treatment of patients with hormone-sensitive prostate cancer: who needs the triplet combination?

M. I. Volkova; K. A. Turupaev

For citations:

Volkova M.I., Turupaev K.A. Role of darolutamide in intensification of treatment of patients with hormone-sensitive prostate cancer: who needs the triplet combination? Cancer Urology. 2025;21(2):89-103. (In Russ.) https://doi.org/10.17650/1726-9776-2025-21-2-89-103

Views PDF (Rus): 9

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Cancer Urology

For citations:

Cookies policy